Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02690805 · ClinicalTrials.gov registry record
Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System
A clinical trial, sponsored by University of California, Irvine.
- Completed
- Registry status
- 16
- Enrollment target
NCT02690805 is a clinical trial that has completed, run by University of California, Irvine. The registered enrollment target is 16 participants.
The verdict
NCT02690805 has completed, sponsored by University of California, Irvine.
- COMPLETED
- Registry status
- 16 participants
- Enrollment target
Study Summary
The purpose of this research study is to investigate the accuracy of a breast imaging system that measures the uptake of the injected radioactive tracer by gamma-ray imaging, known as scinti-mammography (SMM), to diagnose the residual breast cancer after neoadjuvant chemotherapy (NAC) treatment by comparing to MRI.
Interventions
- DEVICE MR-compatible scinti-mammography (MRI-SMM) system
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2015-05 |
| Est. Completion | 2019-01-25 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02690805
The ClinicalTrials.gov registry entry for NCT02690805 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, Irvine, which has 368 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which MR-compatible scinti-mammography (MRI-SMM) system is the first listed.
NCT02690805 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02690805 about?
NCT02690805 is a clinical study titled "Predicting Neoadjuvant Chemotherapy Response by Using a Combined MRI and Scinti-Mammography (MRI-SMM) System". The purpose of this research study is to investigate the accuracy of a breast imaging system that measures the uptake of the injected radioactive tracer by gamma-ray imaging, known as scinti-mammography (SMM), to diagnose the residual breast cancer after neoadjuvant chemotherapy (NAC) treatment by c...
What is the current status of trial NCT02690805?
This trial is currently completed. The enrollment target is 16 participants. The study started on 2015-05. Estimated completion is 2019-01-25.
What interventions are being tested in trial NCT02690805?
The interventions under investigation include: MR-compatible scinti-mammography (MRI-SMM) system (DEVICE).
Who is sponsoring clinical trial NCT02690805?
This trial is sponsored by University of California, Irvine, which has 368 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.